Characterization of and risk factors for the acute-phase response after zoledronic acid

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 9, 2010, Pages 4380-4387

  Reid, I R ^a   Gamble, G D ^a   Mesenbrink, P ^b   Lakatos, P ^c   Black, D M ^d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACUTE PHASE RESPONSE; AGED; ANOREXIA; ARTICLE; ASIAN; BACKACHE; CHILL; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FEVER; EYE INFLAMMATION; EYE PAIN; FATIGUE; FEMALE; GASTROENTERITIS; HEADACHE; HOT FLUSH; HUMAN; INFLUENZA; INSOMNIA; JAPANESE; JOINT STIFFNESS; JOINT SWELLING; MAJOR CLINICAL STUDY; MALAISE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA; NECK PAIN; OCULAR PRURITUS; OSTEOPOROSIS; PERIPHERAL EDEMA; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK ASSESSMENT; SHOULDER PAIN; SIDE EFFECT; SMOKING; SYNCOPE; THIRST; THORAX PAIN; TREMOR; VERTIGO; VOMITING; CHEMICALLY INDUCED; CLASSIFICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ETIOLOGY; IMMUNOLOGY; INCIDENCE; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; VERY ELDERLY;

ACUTE-PHASE REACTION; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMIDAZOLES; INCIDENCE; OSTEOPOROSIS, POSTMENOPAUSAL; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77956566798     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-0597     Document Type: Article

References (19)

1. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR 2007 Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809-1822 (Pubitemid 46698462)
2. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR 2007 Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 22:142-148
3. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S 2007 Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799-1809
4. Roelofs AJ, Jauhiainen M, Mönkkönen H, Rogers MJ, Mönkkönen J, Thompson K 2009 Peripheral blood monocytes are responsible for gamma delta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144:245-250
5. Thompson K, Rogers MJ 2004 Statins prevent bisphosphonate-induced γ, Δ-T-cell proliferation and activation in vitro. J Bone Miner Res 19:278-288
6. 2003 Medical dictionary for regulatory activities (MedDRA). Reston, VA: Northrop Grumman
7. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V 1987 The acute-phase response after bisphosphonate administration. Calcif Tissue Int 41:326-331
8. Bijvoet OL, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H, van Paassen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP 1980 APD in Paget's disease of bone. Arthritis Rheum 23:1193-1204
9. Frijlink WB, te Velde J, Bijvoet OLM, Heynen G 1979 Treatment of Paget's disease with (3-amino-1-hydoxypropylidene)-1,1-bisphosphonate (APD). Lancet 1:799-803
10. Buckler HM, Mercer SJ, Davison CE, Hollis S, Richardson PC, Anderson DG 1998 Evaluation of adverse experiences related to pamidronate infusion in Paget's disease of bone. Ann Rheum Dis 57:572
11. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ 2002 Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653-661 (Pubitemid 34815869)
12. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Löwik CW, Papapoulos SE 1995 Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 10:956-962
13. Sauty A, Pecherstorfer M, Zimmer-Roth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D 1996 Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133-139
14. Thiébaud D, Sauty A, Burckhardt P, Leuenberger P, Sitzler L, Green JR, Kandra A, Zieschang J, Ibarra de Palacios P 1997 An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61:386-392
15. Dicuonzo G, Vincenzi B, Santini D, Avvisati G, Rocci L, Battistoni F, Gavasci M, Borzomati D, Coppola R, Tonini G 2003 Fever after zoledronic acid administration is due to increase in TNF-α and IL-6. J Interferon Cytokine Res 23:649-654
16. Wark J, Recknor C, Ryabitseva O, ChiodoI J, Mesenbrink P, de Villiers T 2010 Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Bone 46(Suppl 1):S33
17. Srivastava T, Haney CJ, Alon US 2009 Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion. J Bone Miner Res 24:334-337
18. Blau LA, Hoehns JD 2003 Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother 37:564-570
19. Chen DY, Chen YM, Ho WL, Chen HH, Shen GH, Lan JL 2009 Diagnostic value of procalcitonin for differentiation between bacterial infection and non-infectious inflammation in febrile patients with active adult-onset Still's disease. Ann Rheum Dis 68:1074-1075